Table 3 Therapeutic efficacy of AM and AL at days 28, 42 and 63 in adult patients in Senegal – IIT and PP analysis
Outcome | Artesunate Mefloquine (n = 157) | Artemether Lumefantrine (n = 153) | p value |
|---|---|---|---|
Intention to treat analysis | |||
Early treatment failure | 00 | 00 | - |
NA | 6 (3.82%) | 4 (2.61%) | 0.77 |
Crude Parasitological failure at day 28 | 1 (0.64%) | 4 (2.61%) | 0.35 |
PCR adjusted failure rate | 1 (0.64%) | 1 (0.65%) | |
PCR adjusted cure rate at day 28 | 150 (95.54%) | 148 (96.73%) | 0.58 |
Artesunate Mefloquine | Artemether Lumefantrine | ||
Per protocol analysis | |||
Early treatment failure | 00 | 00 | - |
Crude parasitological failure | 1/151 (0.66%) | 4/149 (2.6%) | 0.17 |
PCR adjusted failure rate | 1/151 (0.66%) | 1/149 (0.67%) | 0.99 |
PCR adjusted cure rate at day 28 | 150/151 (99.34%) | 148/149 (99.33%) | 0.99 |
Crude parasitological failure at day 42 | 2/70 (2.8%) | 5/57 (8.7% | 0.20 |
PCR adjusted ACPR at day 42 | 69/70 (98.5%) | 56/57 (98.2%) | 1 |
Crude parasitological failure at day 63 | 4/57 (7%) | 6/44 (13%) | 0.32 |
PCR adjusted ACPR at day 63 | 56/57 (98.2%) | 43/44 (97.7%) | 1 |